Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 16/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401087 | 0.87 | IGF1R (0.75) | IGF1RCYP3A4TNK2FGFR1 | |
| SCHEMBL401143 | 0.86 | IGF1R (0.61) | IGF1RCYP3A4TNK2FGFR1 | |
| SCHEMBL399407 | 0.83 | IGF1R (0.59) | IGF1RCYP3A4TNK2FGFR1 | |
| Carbamic Acid SCHEMBL4072218 | 0.81 | IGF1R (0.66) | IGF1RCYP3A4TNK2FGFR1 | |
| Carbamic Acid SCHEMBL4074258 | 0.80 | TNK2 (0.61) | IGF1RCYP3A4TNK2 | |
| SCHEMBL397033 | 0.80 | TNK2 (0.61) | IGF1RCYP3A4TNK2FGFR1 | |
| SCHEMBL400980 | 0.80 | TNK2 (0.72) | TNK2 | |
| SCHEMBL402699 | 0.79 | IGF1R (0.62) | IGF1RCYP3A4TNK2FGFR1 | |
| SCHEMBL400761 | 0.77 | IGF1R (0.78) | IGF1RCYP3A4TNK2FGFR1 | |
| SCHEMBL402214 | 0.77 | IGF1R (0.61) | IGF1RCYP3A4TNK2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |